Introduction
- Status epilepticus is a neurological emergency that requires urgent assessment and treatment with pharmacologic agents.
- Lorazepam and diazepam are short-acting drugs that can produce immediate effects.
- Treatment with another long-acting anticonvulsant drug is necessary to prevent recurrent convulsions.
- Use of IV phenytoin (PHT) for status epilepticus dates back to the 1950s, with fosphenytoin (FPHT) being the primary agent in some institutions.
Pharmacology
| Properties | Phenytoin / Fosphenytoin | Levetiracetam (Keppra) |
|---|---|---|
| Dose | 20 mg/kg PE* (max 1500 mg) | 1–4.5 g IV (40–60 mg/kg) |
| Administration | Max IV infusion PHT 50 mg/min FPHT 150 mg/min | 1.5–2 g IV over ~7 min (2–5 mg/kg/min) |
| Formulation | IV / PO | IV / PO |
| PK / PD | Onset ~30 min** Half-life 12–28 hr Excreted >90% urine | Onset 30–45 min Half-life 6–8 hr Excreted 66% renal |
| Adverse effects | Phlebitis, hypotension, bradycardia & dysrhythmias |
|
| Interactions & warnings | Major CYP3A4 inducer (↓ levels of co-administered drugs) | — |
| Compatibility | PHT – 0.9% NS only (avoid dextrose — precipitates) FPHT – D5W or NS | D5W, NS, or LR |
*PE = phenytoin equivalents. Fosphenytoin requires ~15 min to convert to active phenytoin in addition to the infusion time; confirm dosing and rates against your institution protocol.
Overview of Evidence
| Author, year | Design / sample size | Dosing regimen | Outcome |
|---|---|---|---|
| ESETT (Kapur), 2019 | RCT N=384 | LEV 60 mg/kg (max 4500 mg) vs FOS 20 mg/kg PE (max 1500 mg) vs VPA 40 mg/kg (max 3000 mg) | Seizure cessation at 60 min: LEV 47%, fosphenytoin 45%, valproate 46% — no agent superior. |
| Nakamura, 2017 | Retrospective, historical controls n=63 (21 LEV / 42 FPHT) | LEV 1000 mg vs FPHT 22.5 mg/kg | No significant difference in status epilepticus control (FPHT 81.0% vs LEV 85.1%, p=0.69). The only head-to-head levetiracetam-vs-fosphenytoin study. |
| Gujjar et al, 2017 | Prospective, open-label RCT n=52 SE subgroup (115 total: 52 SE + 63 cluster) | LEV 30 mg/kg vs PHT 20 mg/kg | No statistically significant difference between LEV and PHT for SE control. |
| Chakravarthi, 2015 | RCT n=44 | LEV 20 mg/kg vs PHT 20 mg/kg | LEV and PHT were equally effective at terminating seizures within 30 min and at 24-hour recurrence. |
| Mundlamuri, 2015 | RCT N=150 (50/50/50) | VPA 30 mg/kg vs LEV 25 mg/kg vs PHT 20 mg/kg | Seizure control: PHT 68%, VPA 68%, LEV 78% — no significant difference (p=0.44). |
| Alvarez et al, 2011 | Retrospective n=187 episodes | VPA / LEV / PHT 20 mg/kg after benzodiazepine | Control: VPA 74.6%, PHT 58.6%, LEV 51.7%. LEV failed more often than VPA (adjusted OR 2.69, 95% CI 1.19–6.08). |
| Pediatric & pooled evidence | |||
| ConSEPT (Dalziel), 2019 | Open-label RCT (pediatric) | LEV vs PHT | Pediatric convulsive SE: levetiracetam was not superior to phenytoin as second-line therapy. |
| EcLiPSE (Lyttle), 2019 | Open-label RCT (pediatric) | LEV vs PHT | Pediatric convulsive SE: no significant difference between levetiracetam and phenytoin. |
| DeMott et al, 2020 | Meta-analysis | LEV vs PHT | LEV = PHT for seizure cessation (RR 1.05); no significant difference in efficacy. |
Values are from the primary publications; "no agent superior" reflects the absence of a statistically significant between-arm difference.
Conclusions
- In the pivotal ESETT trial and the supporting head-to-head studies, levetiracetam, fosphenytoin/phenytoin, and valproate are comparably effective second-line agents for benzodiazepine-refractory status epilepticus — no single agent is clearly superior.
- Because efficacy is similar, agent selection is driven by safety, compatibility, and patient-specific factors: phenytoin/fosphenytoin carry phlebitis, hypotension, bradycardia/dysrhythmia risk and are a major CYP3A4 inducer, whereas levetiracetam is renally cleared with a more favorable interaction profile.
- Pediatric RCTs (ConSEPT, EcLiPSE) and the DeMott 2020 meta-analysis reinforce that levetiracetam and phenytoin perform similarly as second-line therapy.
- More recent network meta-analyses (Kishihara 2024; Zhang 2024) suggest phenobarbital may rank highly among second-line options, but the certainty of evidence is very low and it has not displaced levetiracetam, fosphenytoin, or valproate as the mainstays; the 2016 AES guideline still positions these three as the principal second-line choices.
References
- Phenytoin. Micromedex [Electronic version]. Greenwood Village, CO: Truven Health Analytics. Retrieved November 12, 2018, from http://www.micromedexsolutions.com/
- Levetiracetam. Micromedex [Electronic version]. Greenwood Village, CO: Truven Health Analytics. Retrieved November 12, 2018, from http://www.micromedexsolutions.com/
- Alvarez V. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011 Jul;52(7):1292-6.
- Chakravarthi S. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015 Jun;22(6):959-63.
- Mundlamuri RC. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam–Pilot study. Epilepsy Res. 2015 Aug;114:52-8.
- Gujjar AR. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. Seizure. 2017 Jul;49:8-12. doi:10.1016/j.seizure.2017.05.001.
- Nakamura K. Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. Medicine (Baltimore). 2017 Jun;96(25):e7206.
- Bleck T. The established status epilepticus trial 2013. Epilepsia. 2013 Sep;54 Suppl 6:89-92.
- Recent evidence added on review (2019–2024)
- Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus (ESETT). N Engl J Med. 2019 Nov 28;381(22):2103-2113. doi:10.1056/NEJMoa1905795
- Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet. 2019 May 25;393(10186):2125-2134. doi:10.1016/S0140-6736(19)30724-X
- Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet. 2019 May 25;393(10186):2135-2145. doi:10.1016/S0140-6736(19)30722-6
- DeMott JM, Slocum GW, Gottlieb M, Peksa GD. Levetiracetam versus phenytoin for second-line treatment of status epilepticus: a systematic review and meta-analysis. Epilepsy Behav. 2020 Oct;111:107286. doi:10.1016/j.yebeh.2020.107286
- Kishihara Y, Yasuda H, Ishikawa K, et al. Efficacy of second-line anticonvulsant agents for benzodiazepine-resistant convulsive status epilepticus in adults: a systematic review and network meta-analysis. Am J Emerg Med. 2024 Aug;82:183-189. doi:10.1016/j.ajem.2024.06.019
- Zhang Y, et al. Comparative efficacy and safety of second-line medications for status epilepticus: a systematic review and network meta-analysis. Medicine (Baltimore). 2024 Nov 15;103(46):e40333. doi:10.1097/MD.0000000000040333
- Rubinos C, Bruzzone MJ, Blandin V, et al. Emergent management of status epilepticus. Continuum (Minneap Minn). 2024 Jun 1;30(3):682-720. doi:10.1212/CON.0000000000001445
Tags:fosphenytoin
levetiracetam
status epilepticus
ESETT
Source PDF
fosphenytoin-keppra-status.pdfNever Miss a Friday Pearl
Get Pharmacy Pearls in your inbox every Friday
Free weekly clinical pearls written for pharmacists. Practical, evidence-based, and built for bedside use.
Free forever. Unsubscribe anytime. No spam, ever.